There is increasing evidence that the immune response plays a role in the prevention of leukemic relapses after allogeneic bone marrow transplantation (BMT). Producing this effect (referred to as the graft-versus-leukemia reaction or GVL) is a current goal of clinical transplantation. At present, all protocols rely on the injection of donor T cells with unknown specificities. In keeping with this approach, we recently proposed the use of a single allogeneic T cell clone transfected with the HSvtk gene to target an HLA-DPB1 mismatch in the GVH direction. For this strategy to be successful, HLA-DP antigens must be expressed on leukemic cells, which should be recognised by the HLA-DP-specific T cell clone and subsequently destroyed. In the present study, differential expression of HLA-DR, -DQ and -DP was tested by fluorescence using monoclonal antibodies on a panel of 46 acute myeloid leukemias (AML), 28 acute lymphoblastic leukemias (ALL) and 31 chronic lymphocytic leukemias of B cell origin (B-CLL). The vast majority of leukemic cells expressed HLA-DP antigens although with considerable variability. HLA-DPB1 genotyped leukemic cells were used as target cells for an HLA-DPB1*0401-specific T cell clone. Specific recognition of leukemic blasts was demonstrated for 11 out of 11 B-CLL, 11 out of 19 AML and nine out of 16 ALL. These data show that most leukemic blasts are accessible to direct lysis by allogeneic HLA-DP-specific T cells. Keywords: immunotherapy; BMT; GVL; CTL; HLA-DP Clinical studies have demonstrated that alloreactivity after bone marrow transplantation (BMT) is responsible not only for graft-versus-host disease (GVHD) but also for a beneficial effect referred to as graft-versus-leukemia reaction (GVL). Evidence for GVL comes from observations showing the balance between the two aspects of the allogeneic reaction, ie patients who experienced GVHD had fewer relapses than those without GVHD, whereas only those with mild GVHD had improved survival.
GVL are both mediated by donor T lymphocytes, but it is still not possible to determine the subsets responsible for one or the other. Accordingly, most recent efforts to control alloreaction (ie to keep the benefit of GVL while avoiding the mortality and morbidity due to GVHD) have focused on transplanted T cells as a whole. For example, some groups have considered the injection of graded doses of donor T cells either as a preventive regimen [4] [5] [6] or in the case of relapse. [7] [8] [9] [10] [11] [12] [13] More recently, it was suggested that donor T lymphocytes be transduced with the herpes simplex thymidine kinase gene (HSv-tk) before grafting 14 to facilitate their destruction through ganciclovir treatment in the event that GVHD occurs. In the above protocols, whole donor T lymphocyte populations were injected into the recipient. Consequently, neither the relative importance of different HLA target antigens nor the effector T cells involved in the alloreaction were known. Because of genetic diversity, different T cell subsets directed at various HLA class I and HLA class II minor and major antigens will be involved at different frequencies, depending on each recipient-donor combination. Such complexity has two main drawbacks. First, on a patient-per-patient basis, the final outcome of the procedure is not predictable. Secondly, the success or failure of the protocol is particularly difficult to interpret. A simplification of the immunological setting might improve both control of the reaction and our understanding of the final outcome of the graft. In line with this concern, the best-defined immunological situation would be to target a single antigen with a single T cell clone. In this case, what would be the best way to start with a single HLA antigen? We recently proposed taking advantage of two apparently paradoxical observations. Although increased risk of GVHD due to HLA-DPB1 incompatibility is not statistically detectable, 15, 16 HLA-DP-specific T cells can be isolated from skin biopsies at the onset of GVHD each time an HLA-DP mismatch is present. [17] [18] [19] [20] If an HLA-DP mismatch can induce an allogeneic response in vivo, it should be able to trigger both a GVH and a GVL effect (as long as leukemic cells express HLA-DP antigens). We are currently considering the use of HLA-DPB1-specific T cell clones transfected with the viral HSv-tk gene and directed against an HLA-DPB1 mismatch allele in the GVH direction (to spare regenerating hematopoiesis) in order to generate an allogeneic GVH-GVL effect in the context of a T cell-depleted BMT. 21 For this strategy to be successful, HLA-DP antigens should be present on leukemic cells and recognized by an HLA-DP-specific T cell clone with sub-sequent cytotoxicity. Data about the frequency of the HLA-DP genotype and HLA-DP expression on leukemic blasts are lacking, and there is little information on the ability of CD4 + CTL to recognize leukemic blasts. The present study tested the capacity of CD4 + HLA-DP-specific cytotoxic T cell clones to kill a panel of HLA-DP genotyped and phenotyped leukemic blasts from ALL, AML and B-CLL.
Materials and methods

T cell clones and B cell lines
Isolation of the HLA-DPB1*0401-specific T cell clone CTL37: HLA-DPB1*0401-specific T cells were generated in a one-way mixed lymphocyte culture between donor H (HLA A1/A1, B8/B8, DR3/DR3, DQ2/DQ2, DPB1*0101/ DPB1*0201) and donor F (HLA A1/A1, B8/B8, DR3/DR3, DQ2/DQ2, DPB1*0401/DPB1*0401). After separation on Ficoll-Hypaque, 1 ϫ 10 6 PBL from donor H were cocultured with 0.5 ϫ 10 6 PBL (irradiated with 35 Gy) from donor F in 2 ml of RPMI 1640 (GIBCO Life Technologies, Grand Island, NY, USA) supplemented with 10% human serum, 1% l-glutamine and 50 g/ml gentamicin in a 2-ml well of a 24-well culture plate. At day 11, 0.34 ϫ 10 6 T cells were harvested and restimulated with 2.88 ϫ 10 6 (irradiated with 35 Gy) PBL from donor F. Thereafter, the culture was fed three times weekly, and rIL2 (150 BRMP U/ml) was added at day 14. Initial screening of the bulk T cell line demonstrated its specificity for HLA-DPB1*0401 (not shown). Clones were derived from the bulk population as described below and screened against HLA-DPB1*0401 positive and negative BLCL. Clone CTL37 was retained for the present study; its reactivity against a panel of HLA-DPB1 genotyped BLCL is shown in Figure 1 . The HLA-DPB1*1001-specific T cell clone CTLVB2 was derived from the skin biopsy of a patient with acute GVHD after an allogeneic BMT. 20 The B lymphoblastoid cell lines used for specificity testing came from the 1987 HLA workshop in New York or were locally derived from normal donor PBL by incubation in the presence of EBV containing supernatant from the Marmoset B95.8 virus-producing cell line.
Cloning
For cloning (40 days after initiation of the culture), one T cell was seeded in every three culture wells in a 96-microwell round-bottomed culture plate (Nunclon, Copenhagen, Denmark), together with pooled allogeneic feeder cells (5 × 10 5 PBL and 5 × 10 3 of the B lymphoblastoid cell line (BLCL) irradiated with 35 Gy) in the presence of leukoagglutinin-A (1 g/ml) and rIL-2 (150 BRMP U/ml). This stimulation was repeated on emerging clones at day 49. Before specificity assays, T cell clones were cultured without stimulation in rIL2 alone for at least 2 weeks.
Cytotoxic assay
Cytotoxic activity was tested using a standard 51 Cr release assay. Briefly, target cells were labeled with 100 Ci Na 51 2 CrO 4 for 1 h at 37°C, washed four times and then plated at a 10:1 effector-to-target ratio in a 96-well roundbottomed culture plate. After 4 h of incubation at 37°C, 25 l of supernatant from each well were removed and counted in a beta scintillation counter. Each test was performed in triplicate. Results are expressed as the percentage of lysis, according to the following formula: (experimental release -spontaneous release)/(maximal release -spontaneous release) × 100, where experimental release represents mean counts per minute released from target cells in the presence of effector cells, spontaneous release that from target incubated without effector, and maximum release that from target incubated with 1% cetavlon. In some cases, leukemic target cells were washed again but without FCS, incubated 30 min at room temperature with peptide at optimal concentration (1 nm) and then washed in 15 ml of medium. The sensitivity of leukemic cells to CTL lysis was evaluated in two ways: First, leukemic blasts were loaded with HLA-A2 restricted peptides (NA17-A (VLPDVFIRC), or MART-1 (AAGIGILTV), or BMLF1 (GLCTLVAML)) and used as target cells for T cell clones with the corresponding specificity (M17.221, M77.84 and A2.10 specific for HLA A2.1+NA17-A, or +MART-1, or +BMLF1 respectively). Secondly, recognition of HLA-DPB1 molecules was tested using either the CD4 + anti-HLA DPB1*0401-specific T cell clone CTL37, or the CD4 + anti-HLADPB1*1001 T cell clone CTLVB2. The human T cell clones specific for melanoma antigens (NA17-A or MART-1) or Epstein-Barr virus-derived antigen from the protein (BMLF1) have been described elsewhere.
22,23
Proliferation assay
Resting T cells from CTL37 (2.5 ϫ 10 4 ), taken more than 2 weeks after the last stimulation, were cocultured for 48 h with irradiated (35 Gy) BLCL in 96-microwell flat-bottomed culture plates at a 1:1 responder-to-stimulator ratio. Six hours before harvesting, 1 Ci of 3 H thymidine was added to each well, and 3 H thymidine uptake was then measured in a liquid beta scintillation counter. Results are expressed as the mean of triplicate cultures.
Flow cytometry
The mAbs used for flow cytometry were anti-HLA DQ (SPLV3), anti-HLA DR (BL2) (from Immunotech, Marseille, France), anti-HLA DP (B7.21, from Becton Dickinson, Mountain View, CA, USA), anti-HLA A2 (BB7.2 from the ATCC, Rockville, MD, USA) and anti-HLA class I (W6.32 from the ATCC). Their binding was revealed by FITC-conjugated anti-mouse IgG antiserum (green fluorescence) (RAM-FITC from Bioatlantic, Nantes, France). Five thousand labeled cells were analyzed on a FACScan flow cytometer (Becton Dickinson) using LYSIS II software. All mAbs were used at previously tested saturating concentrations. Results were expressed as mean fluorescence minus the background fluorescence obtained with the RAM-FITC alone.
Results
Only samples with more than 80% leukemic blasts (as determined by cytological analysis) were retained for this study. For cytotoxic studies, no further purification of blast cells was performed. For HLA antigen expression by flow cytometry, blast cells were further identified by a morphological criterion (FSC-SSC window on the FACScan).
HLA-DPB1 genotype of leukemic blasts
HLA-DP genotype was performed on 26 ALL, 37 AML and 15 CLL-B. Figure 2 indicates the frequencies of leukemic blasts with at least one of the indicated HLA-DPB1* alleles (phenotypic frequencies), ie for the most frequent 
HLA class I and II expression by leukemic blasts
HLA class I and II expression was tested by immunofluorescence with mAbs used at saturating concentrations. Considerable variability was observed for the three types of leukemic cells tested (see range values in Table 1a ). The following significant differences were observed for a Duncan test at 5%: HLA class-I, HLA-DR and HLA-DP expression was lower on AML than ALL or CLL-B cells, and HLA-DQ expression was higher on CLL-B than AML or ALL cells.
Sensitivity to lysis by CTL directed at HLA-A2+ peptide
Leukemic blast sensitivity to lysis by CTL directed at class I was tested with one of the three T cell clones directed at three different HLA-A2+peptide complexes (see Materials and methods). After screening for HLA-A2 expression (using mAb BB7.2), HLA-A2+ and several HLA-A2Ϫ blasts were kept for further studies. HLA-A2+ and HLA-A2Ϫ leukemic cells loaded with NA17.A, MART-1 or BMLF1 peptides were then used as a target for T cell clones of corresponding specificity (ie M17.221, M77.84, and A2.10, respectively). Against HLA-A2+ target cells, the cytotoxicity score (at a 10-to-1 effector-to-target ratio) ranged from 9 to 43% for AML, 12 to 46% for ALL and 23 to 63% for CLL-B (Table 1b ), indicating that in these conditions each leukemic type tested was recognized and sensitive to CTL lysis although with some variability (Figure 3) . Moreover, no cytotoxicity was detected against unloaded HLA-A2+ or HLA-A2Ϫ leukemic blasts (data not shown) indicating that leukemic cell recognition by CTL was specific.
Leukemic blast sensitivity to lysis by the CD4 + HLA-DPB1*0401 cytotoxic T cell clone CTL37
The data described above were generated using CTL clones directed at HLA-A2+peptide complexes and with target cells loaded in vitro with the corresponding peptides. In these conditions, the number of antigens 'available' for recognition by CTL at the cell surface of leukemic blasts might have been well above the number of naturally presented alloantigens. Consequently, the above data did not preclude the ability of an HLA-specific CTL to kill the same target cells. To address this point, we isolated a CD4 + cytotoxic T cell clone (CTL37) recognizing the most frequent HLA-DPB1 allele, ie HLA-DPB1*0401 (see Methods section). Thereafter, leukemic blasts were genotyped for HLA-DPB1 and used as a target for clone CTL37. The results are summarized in Figure 3 (lower panel) and Table 1b . A threshold is indicated in Figure 3 above which the cytotoxicity score observed against leukemic blasts can be considered specific (Student's t-test Ͻ5%). This threshold was calculated from the values obtained against the irrelevant target blasts, ie HLA-DPB1*0401 negative in this case. No cytotoxicity scores above 6% were observed against the HLA-DPB1*0401 negative leukemic blasts, indicating that clone CTL37 did not exert a significant level of non-specific killing. In contrast, the vast majority of HLA-DPB1*0401 leukemic blasts were killed by CTL37. Nevertheless, considerable variability was observed among cytotoxicity scores, which were not correlated with the mean fluorescence of HLA-DP antigens (data not shown).
Specific recognition of HLA-DPB1 molecules on target cells
Specific recognition of leukemic blasts was documented in several ways. First of all, CTL37 showed no non-specific cytotoxic activity against any of the BLCL tested ( Figure  1) . Secondly, the reproducibility of CTL37 blockage was systematically tested against the target BLCL BTB (the 10 experiments are presented in Figure 1) . Thirdly, to confirm that leukemic blast recognition was always due to a specific mechanism when enough cells were available, blocking experiments were performed against a target cell recognized by CTL37 (using B7.21, the anti HLA-DP mAb). Cytotoxic activity of CTL37 against leukemic blasts was dramatically inhibited in the presence of mAb B7.21 (mean 68%, 59% and 68% for B-CLL, AML and B-ALL, respectively, data not shown). For some patients, a sufficient number of leukemic cells was available to reproduce the blocking experiment and to include mAbs against HLA-DQ and HLA-DR (Table 2 ). These data confirm that leukemic blast recognition was blocked only when HLA-DP antigens were masked at their surface (Table 2) . Finally, specific killing of leukemic blasts through HLA-DP recognition was also documented using the HLA-DPB1*1001 leukemic blasts from two different patients (UPN123 and UPN130): these blasts were recognized by clone CTLBV2 but not by clone CTL37 and their recognition by CTLVB2 was abrogated in the presence of mAb against HLA-DP but not by mAb directed at HLA-DQ or HLA-DR molecules (Figure 4) . 
Discussion
The purpose of this study was to obtain direct cellular evidence that the targeting of an HLA-DP mismatch antigen in the GVH direction with a cytotoxic T cell clone is a useful approach for induction of an antileukemic effect after T cell-depleted BMT. The following points were considered: the number of clones required to treat a majority of patients, whether leukemic blasts express HLA-DP antigens and whether they can be killed by an HLA-DPB1* 0401 allospecific cytotoxic T cell clone. HLA class I and class II (-DR, -DQ and -DP) expression was tested on 105 fresh leukemic blasts from AML, B-ALL and B-CLL, 78 of which were genotyped for HLA-DPB1. Altogether, 96.5% of the leukemic cells presented at least one of the following alleles: HLA-DPB1*0201, 0301 or 0401. Thus, only three CTL directed against these antigens would be sufficient to treat nearly all patients. The vast majority of leukemic cells expressed detectable levels of HLA-DP antigens. A comparison of HLA-antigen expression in the different leukemic cells tested confirmed that HLA class I, HLA-DR and HLA-DP expression was lower in AML than B-ALL or B-CLL cells and indicated that HLA-DQ expression was higher in B-CLL than AML or ALL cells.
After screening for HLA phenotype and genotype, fresh leukemic blasts were tested for their sensitivity to CTL lysis. It is now well documented that the majority of alloreactive T cell clones recognize an allo-MHC molecule+peptide complex (see Ref. 24 for review). As the panel of peptides presented at the cell surface within a given HLA molecule might differ somewhat from one cell type to another, the recognition of different leukemic blasts by the same alloreactive T cell clone could be potentially influenced not only by the number of HLA molecules expressed at the leukemic cell surface but also by the type of blast tested. Thus, to test blast sensitivity to lysis independently of the qualitative TCR-CMH+peptide complex interaction, we designed a protocol in which TCR CMH+peptide interaction was the same for all blasts tested. This involved the use of three T cell clones recognizing known HLA-A2+peptides complexes. These HLAA2+peptide complexes were induced at the leukemic cell surface by incubation in the presence of the appropriate peptide. Loaded blasts were then used as a target for T cell clones with the corresponding specificity. This test allowed us to analyze the possible intrinsic resistance of some leukemic cell populations to CTL lysis independently of the qualitative MHC+peptide+TCR interaction. In these conditions, all leukemic blast populations were recognized (with some variability) by the CTL tested, in particular those B-CLL blasts previously considered as quite resistant to direct cell-mediated killing. 25, 26 Finally, a majority of HLA-DPB1*0401 leukemic cells were also killed by clone CTL37. It is not clear why some blasts were not recognized, and analysis of this situation was difficult due to the limited number of negative blast cells available. On leukemic cells, the presence or absence of adhesion or regulatory molecules, such as ICAM-I, LFA-1, B7.1, B7.2 or Fas-L (as recently demonstrated for some solid tumors), can affect their ability to sustain a primary response as well as their direct recognition by differentiated CTL. Because peptideloaded leukemic cells were sensitive to direct CTL lysis, it seemed unlikely that some had a negative counteraction of any sort with the effector T cell clone. In the case of HLA-DPB1*0401 leukemic blasts recognized by CTL37, it is noteworthy that no correlation was observed between the level of HLA-DP expression estimated by flow cytometry and the cytotoxicity score. Thus, in the context of a clinical protocol, a direct cytotoxic assay between fresh patient leukemic blasts and the CTL clone to be injected should be one of the inclusion criteria. Taken together, these results seem promising enough to warrant a phase I clinical trial using a subclone of CTL37, tranfected with a suicide gene in order to control in vivo the alloreaction, should GVHD occur. Using HLA-DP-specific T cell clones to produce a GVH-GVL effect would have two main advantages. First, as 70% of unrelated HLA-A, -B, -DR-identical BMT are HLA-DP-mismatched, HLA-DP targeting would allow a phase I clinical trial to be considered in an otherwise immunologically classic BMT. Moreover, although there is a tendency to use donor T cell clones for such an application, it may be possible to use third party-specific T cell clones because of the drastic immunosuppression associated with T cell-depleted BMT early after transplantation. If this proves feasible, the second advantage concerns the fact that some HLA-DPB1 alleles (HLA-DPB1*0401, 402, 101, 201, 301) are observed much more frequently than others. Consequently, the use of a few clones would allow the treatment of a majority of patients. Finally, besides the specific concern of this study, these data also provide direct cellular evidence that allospecific T cells, which are responsible for GVHD might also be directly responsible for the anti-leukemic effect.
